Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Metrics to compare | CING | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | −2.4x | −0.5x | |
PEG Ratio | −0.03 | −0.05 | 0.00 | |
Price/Book | 15.9x | 2.0x | 2.6x | |
Price / LTM Sales | - | 1.6x | 3.3x | |
Upside (Analyst Target) | 179.1% | 316.7% | 45.7% | |
Fair Value Upside | Unlock | 20.2% | 6.5% | Unlock |